{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:44:34Z","timestamp":1787499874945,"version":"build-2736575974"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s11739-022-03139-x","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T17:02:50Z","timestamp":1668099770000},"page":"31-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["NAFLD as the metabolic hallmark of obesity"],"prefix":"10.1007","volume":"18","author":[{"given":"Alba","family":"Rojano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Manzano-Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Peric\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-0203","authenticated-orcid":false,"given":"Andreea","family":"Ciudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"issue":"1","key":"3139_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence. Incidence Outcomes Hepatol 64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Incidence Outcomes Hepatol"},{"key":"3139_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"The GBD 2015 Obesity Collaborators","year":"2015","unstructured":"The GBD 2015 Obesity Collaborators (2015) Obesity Collaborators. (2017) Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 377:13\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1614362","journal-title":"N Engl J Med"},{"key":"3139_CR3","unstructured":"Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (accessed 2022\u201308\u201311)."},{"issue":"8","key":"3139_CR4","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65(8):1038\u20131048. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012","journal-title":"Metabolism"},{"key":"3139_CR5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","volume":"387","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2016","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) (2016) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19\u00b72 million participants. Lancet 387:1377\u20131396. https:\/\/doi.org\/10.1016\/S0140-6736(16)30054-X","journal-title":"Lancet"},{"key":"3139_CR6","first-page":"404","volume":"34","author":"E Cholongitas","year":"2021","unstructured":"Cholongitas E, Pavlopoulou I, Papatheodoridi M, Markakis GE, Bouras E, Haidich A-B, Papatheodoridis G (2021) Epidemiology of nonalcoholic fatty liver disease in europe: a systematic review and meta-analysis. Ann Gastroenterol 34:404\u2013414","journal-title":"Ann Gastroenterol"},{"key":"3139_CR7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/hep.25772","volume":"56","author":"R Loomba","year":"2012","unstructured":"Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM (2012) The nonalcoholic steatohepatitis clinical research network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 56:943\u2013951. https:\/\/doi.org\/10.1002\/hep.25772","journal-title":"Hepatology"},{"issue":"1","key":"3139_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","volume":"140","author":"CD Williams","year":"2011","unstructured":"Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140(1):124\u2013131. https:\/\/doi.org\/10.1053\/j.gastro.2010.09.038","journal-title":"Gastroenterology"},{"issue":"2","key":"3139_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00431-013-2157-6","volume":"173","author":"S Berardis","year":"2014","unstructured":"Berardis S, Sokal E (2014) Pediatric non-alcoholic fatty liver disease: an increasing public health issue. Eur J Pediatr 173(2):131\u2013139","journal-title":"Eur J Pediatr"},{"issue":"10","key":"3139_CR10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/obr.12904","volume":"20","author":"V Sharma","year":"2019","unstructured":"Sharma V, Coleman S, Nixon J, Sharples L, Hamilton-Shield J, Rutter H, Bryant M (2019) A systematic review and meta-analysis estimating the population prevalence of comorbidities in children and adolescents aged 5 to 18 years. Obes Rev 20(10):1341\u20131349. https:\/\/doi.org\/10.1111\/obr.12904","journal-title":"Obes Rev"},{"issue":"1 Suppl","key":"3139_CR11","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62(1 Suppl):S47-64. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012","journal-title":"J Hepatol"},{"issue":"7","key":"3139_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD (2021) Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 6(7):578\u2013588. https:\/\/doi.org\/10.1016\/S2468-1253(21)00020-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"3139_CR13","doi-asserted-by":"publisher","first-page":"E57","DOI":"10.3390\/children4070057","volume":"4","author":"A Di Sessa","year":"2017","unstructured":"Di Sessa A, Umano GR, Miraglia Del Giudice E (2017) The association between non-alcoholic fatty liver disease and cardiovascular risk in children. Children (Basel) 4(7):E57. https:\/\/doi.org\/10.3390\/children4070057","journal-title":"Children (Basel)"},{"key":"3139_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cphy.c110062","volume":"3","author":"CK Roberts","year":"2013","unstructured":"Roberts CK, Hevener AL, James Barnard R (2013) Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol 3:1\u201358. https:\/\/doi.org\/10.1002\/cphy.c110062","journal-title":"Compr Physiol"},{"issue":"8","key":"3139_CR15","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","volume":"50","author":"G Marchesini","year":"2001","unstructured":"Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50(8):1844\u20131850. https:\/\/doi.org\/10.2337\/diabetes.50.8.1844","journal-title":"Diabetes"},{"issue":"10","key":"3139_CR16","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s00018-016-2161-x","volume":"73","author":"W Liu","year":"2016","unstructured":"Liu W, Baker RD, Bhatia T, Zhu L, Baker SS (2016) Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci 73(10):1969\u20131987. https:\/\/doi.org\/10.1007\/s00018-016-2161-x","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"3139_CR17","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24(7):908\u2013922. https:\/\/doi.org\/10.1038\/s41591-018-0104-9","journal-title":"Nat Med"},{"issue":"1","key":"3139_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","volume":"60","author":"J Dyson","year":"2014","unstructured":"Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, Aslam T, Patanwala I, Gaggar S, Cole M, Sumpter K, Stewart S, Rose J, Hudson M, Manas D, Reeves HL (2014) Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 60(1):110\u2013117. https:\/\/doi.org\/10.1016\/j.jhep.2013.08.011","journal-title":"J Hepatol"},{"issue":"6","key":"3139_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","volume":"65","author":"R Pais","year":"2016","unstructured":"Pais R, Barritt AS, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F (2016) NAFLD and liver transplantation: current burden and expected challenges. J Hepatol 65(6):1245\u20131257. https:\/\/doi.org\/10.1016\/j.jhep.2016.07.033","journal-title":"J Hepatol"},{"key":"3139_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cgh.2018.07.006","volume":"17","author":"Y Kim","year":"2019","unstructured":"Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S (2019) Obesity and weight gain are associated with progression of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 17:543\u2013550. https:\/\/doi.org\/10.1016\/j.cgh.2018.07.006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"3139_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"3139_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/TP.0000000000002876","volume":"104","author":"I M\u00edkov\u00e1","year":"2020","unstructured":"M\u00edkov\u00e1 I, Neroldov\u00e1 M, Hub\u00e1cek JA, Dlouh\u00e1 D, Jirsa M, Honsov\u00e1 E, Sticov\u00e1 E, L\u00e1nsk\u00e1 V, \u0160pic\u00e1k J, Trunecka P (2020) Donor PNPLA3 and TM6SF2 variant alleles confer additive risks for graft steatosis after liver transplantation. Transplantation 104(3):526\u2013534. https:\/\/doi.org\/10.1097\/TP.0000000000002876","journal-title":"Transplantation"},{"issue":"2","key":"3139_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/antiox10020270","volume":"10","author":"L Rinaldi","year":"2021","unstructured":"Rinaldi L, Pafundi PC, Galiero R, Caturano A, Morone MV, Silvestri C, Giordano M, Salvatore T, Sasso FC (2021) Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A Narrative Review Antioxidants 10(2):270. https:\/\/doi.org\/10.3390\/antiox10020270","journal-title":"A Narrative Review Antioxidants"},{"issue":"4","key":"3139_CR24","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/hep.23622","volume":"51","author":"L Valenti","year":"2010","unstructured":"Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP (2010) Homozygosity for the patatin-like phospholipase-3\/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51(4):1209\u20131217. https:\/\/doi.org\/10.1002\/hep.23622","journal-title":"Hepatology"},{"issue":"5","key":"3139_CR25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/biomedicines10051015","volume":"10","author":"P Gabriel-Medina","year":"2022","unstructured":"Gabriel-Medina P, Ferrer-Costa R, Rodriguez-Frias F, Ciudin A, Augustin S, Rivera-Esteban J, Peric\u00e0s JM, Selva DM (2022) Influence of type 2 diabetes in the association of PNPLA3 Rs738409 and TM6SF2 Rs58542926 polymorphisms in NASH advanced liver fibrosis. Biomedicines 10(5):1015. https:\/\/doi.org\/10.3390\/biomedicines10051015","journal-title":"Biomedicines"},{"key":"3139_CR26","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J (2020) International consensus panel. mafld: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158:1999\u20132014. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312","journal-title":"Gastroenterology"},{"issue":"1","key":"3139_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wong VW-S, Dufour J-F, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-J\u00e4rvinen H, Fan J-G, Gr\u00f8nb\u00e6k H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng M-H, Fouad Y, Chan W-K, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J (2020) A New definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73(1):202\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"issue":"7","key":"3139_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","volume":"17","author":"H Tilg","year":"2020","unstructured":"Tilg H, Effenberger M (2020) From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 17(7):387\u2013388. https:\/\/doi.org\/10.1038\/s41575-020-0316-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7 Suppl","key":"3139_CR29","first-page":"s176","volume":"22","author":"CM Apovian","year":"2016","unstructured":"Apovian CM (2016) Obesity: definition, comorbidities, causes, and burden. Am J Manag Care 22(7 Suppl):s176-185","journal-title":"Am J Manag Care"},{"key":"3139_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","volume":"15","author":"KG Alberti","year":"1998","unstructured":"Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and Its complications. part 1: diagnosis and classification of diabetes mellitus provisional report of a who consultation. Diabet Med 15:539\u2013553","journal-title":"Diabet Med"},{"issue":"3","key":"3139_CR31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.4158\/EP161688.PS","volume":"23","author":"JI Mechanick","year":"2017","unstructured":"Mechanick JI, Hurley DL, Garvey WT (2017) Adiposity-based chronic disease as a new diagnostic term: The American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement. Endocr Pract 23(3):372\u2013378. https:\/\/doi.org\/10.4158\/EP161688.PS","journal-title":"Endocr Pract"},{"issue":"2","key":"3139_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000497124","volume":"12","author":"G Fr\u00fchbeck","year":"2019","unstructured":"Fr\u00fchbeck G, Busetto L, Dicker D, Yumuk V, Goossens GH, Hebebrand J, Halford JGC, Farpour-Lambert NJ, Blaak EE, Woodward E, Toplak H (2019) The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications. Obes Facts 12(2):131\u2013136. https:\/\/doi.org\/10.1159\/000497124","journal-title":"Obes Facts"},{"key":"3139_CR33","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.4065\/mcp.2010.0583","volume":"85","author":"S Snitker","year":"2010","unstructured":"Snitker S (2010) Use of body fatness cutoff points. Mayo Clin Proc 85:1057\u20131058. https:\/\/doi.org\/10.4065\/mcp.2010.0583","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"3139_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eprac.2021.11.082","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT (2022) Is obesity or adiposity-based chronic disease curable: the set point theory, the environment, and second-generation medications. Endocr Pract 28(2):214\u2013222. https:\/\/doi.org\/10.1016\/j.eprac.2021.11.082","journal-title":"Endocr Pract"},{"issue":"3","key":"3139_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/00365521.2021.1879244","volume":"56","author":"Y-X Shi","year":"2021","unstructured":"Shi Y-X, Chen X-Y, Qiu H-N, Jiang W-R, Zhang M-Y, Huang Y-P, Ji Y-P, Zhang S, Li C-J, Lin J-N (2021) Visceral fat area to appendicular muscle mass ratio as a predictor for nonalcoholic fatty liver disease independent of obesity. Scand J Gastroenterol 56(3):312\u2013320. https:\/\/doi.org\/10.1080\/00365521.2021.1879244","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"3139_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00109-009-0464-1","volume":"87","author":"M Malaguarnera","year":"2009","unstructured":"Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L (2009) Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) 87(7):679\u2013695. https:\/\/doi.org\/10.1007\/s00109-009-0464-1","journal-title":"J Mol Med (Berl)"},{"issue":"6","key":"3139_CR37","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s12072-019-09996-7","volume":"13","author":"JA Kim","year":"2019","unstructured":"Kim JA, Choi KM (2019) Sarcopenia and fatty liver disease. Hepatol Int 13(6):674\u2013687. https:\/\/doi.org\/10.1007\/s12072-019-09996-7","journal-title":"Hepatol Int"},{"issue":"1","key":"3139_CR38","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12876-021-01748-y","volume":"21","author":"T Miyake","year":"2021","unstructured":"Miyake T, Miyazaki M, Yoshida O, Kanzaki S, Nakaguchi H, Nakamura Y, Watanabe T, Yamamoto Y, Koizumi Y, Tokumoto Y, Hirooka M, Furukawa S, Takeshita E, Kumagi T, Ikeda Y, Abe M, Toshimitsu K, Matsuura B, Hiasa Y (2021) Relationship between body composition and the histology of non-alcoholic fatty liver disease: a cross-sectional study. BMC Gastroenterol 21(1):170. https:\/\/doi.org\/10.1186\/s12876-021-01748-y","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"3139_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S (2018) Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 68(2):268\u2013279. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.003","journal-title":"J Hepatol"},{"issue":"12","key":"3139_CR40","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.2337\/diabetes.53.12.3048","volume":"53","author":"M Krssak","year":"2004","unstructured":"Krssak M, Brehm A, Bernroider E, Anderwald C, Nowotny P, Dalla Man C, Cobelli C, Cline GW, Shulman GI, Waldh\u00e4usl W, Roden M (2004) Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 53(12):3048\u20133056. https:\/\/doi.org\/10.2337\/diabetes.53.12.3048","journal-title":"Diabetes"},{"issue":"4","key":"3139_CR41","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2337\/dc15-1876","volume":"39","author":"R Lomonaco","year":"2016","unstructured":"Lomonaco R, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsak B, Biernacki D, Lo M, Suman A, Weber MH, Cusi K (2016) Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes. Diabetes Care 39(4):632\u2013638. https:\/\/doi.org\/10.2337\/dc15-1876","journal-title":"Diabetes Care"},{"issue":"9","key":"3139_CR42","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/oby.2010.77","volume":"18","author":"KM Utzschneider","year":"2010","unstructured":"Utzschneider KM, Van de Lagemaat A, Faulenbach MV, Goedecke JH, Carr DB, Boyko EJ, Fujimoto WY, Kahn SE (2010) Insulin resistance is the best predictor of the metabolic syndrome in subjects with a first-degree relative with type 2 diabetes. Obesity (Silver Spring) 18(9):1781\u20131787. https:\/\/doi.org\/10.1038\/oby.2010.77","journal-title":"Obesity (Silver Spring)"},{"key":"3139_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101238","volume":"50","author":"J Heeren","year":"2021","unstructured":"Heeren J, Scheja L (2021) Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab 50:101238. https:\/\/doi.org\/10.1016\/j.molmet.2021.101238","journal-title":"Mol Metab"},{"issue":"20","key":"3139_CR44","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJM200011163432007","volume":"343","author":"H Tilg","year":"2000","unstructured":"Tilg H, Diehl AM (2000) Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343(20):1467\u20131476. https:\/\/doi.org\/10.1056\/NEJM200011163432007","journal-title":"N Engl J Med"},{"issue":"5","key":"3139_CR45","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1053\/gast.2001.23256","volume":"120","author":"AJ Sanyal","year":"2001","unstructured":"Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120(5):1183\u20131192. https:\/\/doi.org\/10.1053\/gast.2001.23256","journal-title":"Gastroenterology"},{"key":"3139_CR46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.37349\/emed.2020.00011","volume":"1","author":"M Ryou","year":"2020","unstructured":"Ryou M, Stylopoulos N, Baffy G (2020) Nonalcoholic fatty liver disease and portal hypertension. Explor Med 1:149\u2013169","journal-title":"Explor Med"},{"issue":"12","key":"3139_CR47","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/MEG.0b013e32833f14a1","volume":"22","author":"S Francque","year":"2010","unstructured":"Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, Van Gaal L, Michielsen P (2010) Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. Eur J Gastroenterol Hepatol 22(12):1449\u20131457. https:\/\/doi.org\/10.1097\/MEG.0b013e32833f14a1","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"3139_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032785","volume":"7","author":"M Pasar\u00edn","year":"2012","unstructured":"Pasar\u00edn M, La Mura V, Gracia-Sancho J, Garc\u00eda-Calder\u00f3 H, Rodr\u00edguez-Vilarrupla A, Garc\u00eda-Pag\u00e1n JC, Bosch J, Abraldes JG (2012) Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS ONE 7(4):e32785. https:\/\/doi.org\/10.1371\/journal.pone.0032785","journal-title":"PLoS ONE"},{"issue":"7","key":"3139_CR49","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s10620-016-4044-2","volume":"61","author":"KE Corey","year":"2016","unstructured":"Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C (2016) Screening for Nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis. Dig Dis Sci 61(7):2108\u20132117. https:\/\/doi.org\/10.1007\/s10620-016-4044-2","journal-title":"Dig Dis Sci"},{"key":"3139_CR50","doi-asserted-by":"publisher","unstructured":"(2016) EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. J Hepatol 64(6):1388\u20131402. https:\/\/doi.org\/10.1007\/s10620-016-4044-2.","DOI":"10.1007\/s10620-016-4044-2"},{"key":"3139_CR51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.dld.2017.01.147","volume":"49","author":"Italian Association for the Study of the Liver (AISF)","year":"2017","unstructured":"Italian Association for the Study of the Liver (AISF) (2017) AISF position paper on nonalcoholic fatty liver disease (nafld): updates and future directions. Dig Liver Dis 49:471\u2013483. https:\/\/doi.org\/10.1016\/j.dld.2017.01.147","journal-title":"Dig Liver Dis"},{"issue":"1","key":"3139_CR52","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases. Hepatology 67(1):328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367","journal-title":"Hepatology"},{"issue":"3","key":"3139_CR53","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1381\/0960892053576820","volume":"15","author":"JP Ong","year":"2005","unstructured":"Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM (2005) Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 15(3):310\u2013315. https:\/\/doi.org\/10.1381\/0960892053576820","journal-title":"Obes Surg"},{"key":"3139_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12226","author":"S Verma","year":"2013","unstructured":"Verma S, Jensen D, Hart J, Mohanty S (2013) Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int Off J Int Assoc Study Liver. https:\/\/doi.org\/10.1111\/liv.12226","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"7","key":"3139_CR55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"J-H Lee","year":"2010","unstructured":"Lee J-H, Kim D, Kim HJ, Lee C-H, Yang JI, Kim W, Kim YJ, Yoon J-H, Cho S-H, Sung M-W, Lee H-S (2010) Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 42(7):503\u2013508. https:\/\/doi.org\/10.1016\/j.dld.2009.08.002","journal-title":"Dig Liver Dis"},{"key":"3139_CR56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33. https:\/\/doi.org\/10.1186\/1471-230X-6-33","journal-title":"BMC Gastroenterol"},{"key":"3139_CR57","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10396-021-01106-1","volume":"48","author":"G Ferraioli","year":"2021","unstructured":"Ferraioli G (2021) Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens). J Med Ultrason 48:489\u2013495. https:\/\/doi.org\/10.1007\/s10396-021-01106-1","journal-title":"J Med Ultrason"},{"issue":"4","key":"3139_CR58","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11695-010-0204-1","volume":"21","author":"ZM Younossi","year":"2011","unstructured":"Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, Afendy A, Younoszai Z, Goodman Z, Baranova A (2011) A Biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 21(4):431\u2013439. https:\/\/doi.org\/10.1007\/s11695-010-0204-1","journal-title":"Obes Surg"},{"key":"3139_CR59","unstructured":"Overview | Non-alcoholic fatty liver disease (NAFLD): assessment and management | Guidance | NICE. https:\/\/www.nice.org.uk\/guidance\/ng49 (accessed 2022\u201308\u201313)."},{"issue":"2","key":"3139_CR60","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","volume":"68","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Chalasani N (2018) Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol 68(2):305\u2013315. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.013","journal-title":"J Hepatol"},{"issue":"5","key":"3139_CR61","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156(5):1264-1281.e4. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036","journal-title":"Gastroenterology"},{"key":"3139_CR62","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C (2022) Baveno VII Faculty. baveno VII-renewing consensus in portal hypertension. J Hepatol 76:959\u2013974. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.022","journal-title":"J Hepatol"},{"key":"3139_CR63","doi-asserted-by":"publisher","first-page":"723","DOI":"10.14309\/ajg.0000000000000994","volume":"116","author":"M Pons","year":"2021","unstructured":"Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, Stefanescu H, Ma MM, Mandorfer M, Mergeay-Fabre M, Procopet B, Schwabl P, Ferlitsch A, Semmler G, Berzigotti A, Tsochatzis E, Bureau C, Reiberger T, Bosch J, Abraldes JG, Genesc\u00e0 J (2021) Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol 116:723\u2013732","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"3139_CR64","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.cgh.2020.05.034","volume":"19","author":"DH Lee","year":"2021","unstructured":"Lee DH, Cho EJ, Bae JS, Lee JY, Yu SJ, Kim H, Lee KB, Han JK, Choi BI (2021) Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 19(4):797-805.e7. https:\/\/doi.org\/10.1016\/j.cgh.2020.05.034","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3139_CR65","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu Y-C, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ (2005) onalcoholic steatohepatitis clinical research network. design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313\u20131321. https:\/\/doi.org\/10.1002\/hep.20701","journal-title":"Hepatology"},{"issue":"3","key":"3139_CR66","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/hep.20092","volume":"39","author":"KD Lindor","year":"2004","unstructured":"Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P (2004) Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39(3):770\u2013778. https:\/\/doi.org\/10.1002\/hep.20092","journal-title":"Hepatology"},{"issue":"11","key":"3139_CR67","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1172\/JCI94585","volume":"127","author":"S Softic","year":"2017","unstructured":"Softic S, Gupta MK, Wang G-X, Fujisaka S, O\u2019Neill BT, Rao TN, Willoughby J, Harbison C, Fitzgerald K, Ilkayeva O, Newgard CB, Cohen DE, Kahn CR (2017) Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. J Clin Invest 127(11):4059\u20134074. https:\/\/doi.org\/10.1172\/JCI94585","journal-title":"J Clin Invest"},{"issue":"5","key":"3139_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061551","volume":"8","author":"JR Colca","year":"2013","unstructured":"Colca JR, McDonald WG, Cavey GS, Cole SL, Holewa DD, Brightwell-Conrad AS, Wolfe CL, Wheeler JS, Coulter KR, Kilkuskie PM, Gracheva E, Korshunova Y, Trusgnich M, Karr R, Wiley SE, Divakaruni AS, Murphy AN, Vigueira PA, Finck BN, Kletzien RF (2013) Identification of a Mitochondrial target of thiazolidinedione insulin sensitizers (mtot)\u2013relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS ONE 8(5):e61551. https:\/\/doi.org\/10.1371\/journal.pone.0061551","journal-title":"PLoS ONE"},{"issue":"4","key":"3139_CR69","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cmet.2015.07.028","volume":"22","author":"KS McCommis","year":"2015","unstructured":"McCommis KS, Chen Z, Fu X, McDonald WG, Colca JR, Kletzien RF, Burgess SC, Finck BN (2015) Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling. Cell Metab 22(4):682\u2013694. https:\/\/doi.org\/10.1016\/j.cmet.2015.07.028","journal-title":"Cell Metab"},{"issue":"5","key":"3139_CR70","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z (2022) American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (AASLD). Endocr Pract 28(5):528\u2013562. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010","journal-title":"Endocr Pract"},{"issue":"6","key":"3139_CR71","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64(6):1388\u20131402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004","journal-title":"J Hepatol"},{"issue":"12","key":"3139_CR72","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1111\/liv.13480","volume":"37","author":"E Vilar-Gomez","year":"2017","unstructured":"Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Lazo-Del Vallin S, Diago M, Adams LA (2017) Serum Biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. Liver Int 37(12):1887\u20131896. https:\/\/doi.org\/10.1111\/liv.13480","journal-title":"Liver Int"},{"issue":"22","key":"3139_CR73","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355(22):2297\u20132307. https:\/\/doi.org\/10.1056\/NEJMoa060326","journal-title":"N Engl J Med"},{"issue":"8","key":"3139_CR74","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, Bansal B, Kaur P, Jevalikar G, Gill HK, Choudhary NS, Mithal A (2018) Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 41(8):1801\u20131808. https:\/\/doi.org\/10.2337\/dc18-0165","journal-title":"Diabetes Care"},{"issue":"4","key":"3139_CR75","doi-asserted-by":"publisher","first-page":"E387","DOI":"10.3390\/nu9040387","volume":"9","author":"H Kitade","year":"2017","unstructured":"Kitade H, Chen G, Ni Y, Ota T (2017) Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients 9(4):E387. https:\/\/doi.org\/10.3390\/nu9040387","journal-title":"Nutrients"},{"issue":"29","key":"3139_CR76","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.3748\/wjg.v17.i29.3377","volume":"17","author":"S Zelber-Sagi","year":"2011","unstructured":"Zelber-Sagi S, Ratziu V, Oren R (2011) Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 17(29):3377\u20133389. https:\/\/doi.org\/10.3748\/wjg.v17.i29.3377","journal-title":"World J Gastroenterol"},{"issue":"2","key":"3139_CR77","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1053\/jhep.2003.50316","volume":"38","author":"M Kugelmas","year":"2003","unstructured":"Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ (2003) Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38(2):413\u2013419. https:\/\/doi.org\/10.1053\/jhep.2003.50316","journal-title":"Hepatology"},{"issue":"12","key":"3139_CR78","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1038\/oby.2009.126","volume":"17","author":"K Shah","year":"2009","unstructured":"Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT (2009) Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 17(12):2162\u20132168. https:\/\/doi.org\/10.1038\/oby.2009.126","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"3139_CR79","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","volume":"59","author":"MC Ryan","year":"2013","unstructured":"Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, O\u2019Dea K, Desmond PV, Johnson NA, Wilson AM (2013) The mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 59(1):138\u2013143. https:\/\/doi.org\/10.1016\/j.jhep.2013.02.012","journal-title":"J Hepatol"},{"issue":"22","key":"3139_CR80","doi-asserted-by":"publisher","first-page":"00235","DOI":"10.1016\/j.jhep.2022.04.003","volume":"S0168\u20138278","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH, Buchholtz K, Kj\u00e6r MS, Balendran C, Myers RP, Loomba R, Noureddin M (2022) Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised. Open-Label Phase II Trial J Hepatol S0168\u20138278(22):00235\u201300245. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.003","journal-title":"Open-Label Phase II Trial J Hepatol"},{"key":"3139_CR81","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling A-S, Harrison SA (2021) NN9931\u20134296 investigators. a placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"3139_CR82","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT (2022) STEP 8 investigators. effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. The step 8 randomized clinical trial. JAMA 327:138\u2013150. https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"JAMA"},{"issue":"10019","key":"3139_CR83","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, H\u00fcbscher SG, Newsome PN (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet 387(10019):679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X","journal-title":"The Lancet"},{"key":"3139_CR84","doi-asserted-by":"publisher","unstructured":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis | NEJM. https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa2028395 (accessed 2022\u201308\u201314)","DOI":"10.1056\/NEJMoa2028395"},{"issue":"3","key":"3139_CR85","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","volume":"51","author":"AB Mayerson","year":"2002","unstructured":"Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF (2002) The Effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51(3):797\u2013802. https:\/\/doi.org\/10.2337\/diabetes.51.3.797","journal-title":"Diabetes"},{"issue":"1","key":"3139_CR86","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","volume":"13","author":"B Gross","year":"2017","unstructured":"Gross B, Pawlak M, Lefebvre P, Staels B (2017) PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol 13(1):36\u201349. https:\/\/doi.org\/10.1038\/nrendo.2016.135","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"3139_CR87","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1053\/gast.2002.33666","volume":"122","author":"A Galli","year":"2002","unstructured":"Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, Casini A (2002) Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122(7):1924\u20131940. https:\/\/doi.org\/10.1053\/gast.2002.33666","journal-title":"Gastroenterology"},{"issue":"5","key":"3139_CR88","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","volume":"177","author":"G Musso","year":"2017","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R (2017) Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 177(5):633\u2013640. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9607","journal-title":"JAMA Intern Med"},{"issue":"22","key":"3139_CR89","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"21","key":"3139_CR90","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMc1712572","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(21):2099. https:\/\/doi.org\/10.1056\/NEJMc1712572","journal-title":"N Engl J Med"},{"issue":"4","key":"3139_CR91","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde A-M, Sabatine MS (2019) Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"3139_CR92","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejphar.2017.05.019","volume":"809","author":"A Tahara","year":"2017","unstructured":"Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E (2017) Characterization and comparison of SGLT2 inhibitors: part 3. Effects on diabetic complications in type 2 diabetic mice. Eur J Pharmacol 809:163\u2013171. https:\/\/doi.org\/10.1016\/j.ejphar.2017.05.019","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3139_CR93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","volume":"20","author":"B Gaborit","year":"2021","unstructured":"Gaborit B, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, Soghomonian A, Houssays M, Varlet I, Eisinger M, Lasbleiz A, Peiretti F, Bornet CE, Lefur Y, Pini L, Rapacchi S, Bernard M, Resseguier N, Darmon P, Kober F, Dutour A (2021) Effect of empagliflozin on ectopic fat stores and myocardial energetics in Type 2 diabetes: The EMPACEF Study. Cardiovasc Diabetol 20(1):57. https:\/\/doi.org\/10.1186\/s12933-021-01237-2","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"3139_CR94","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/liv.13634","volume":"38","author":"MR Jain","year":"2018","unstructured":"Jain MR, Giri SR, Bhoi B, Trivedi C, Rath A, Rathod R, Ranvir R, Kadam S, Patel H, Swain P, Roy SS, Das N, Karmakar E, Wahli W, Patel PR (2018) Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int 38(6):1084\u20131094. https:\/\/doi.org\/10.1111\/liv.13634","journal-title":"Liver Int"},{"key":"3139_CR95","unstructured":"Inventiva\u2019s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH). Inventiva Pharma. https:\/\/inventivapharma.com\/inventivas-lanifibranor-meets-the-primary-and-key-secondary-endpoints-in-the-phase-iib-native-clinical-trial-in-non-alcoholic-steatohepatitis-nash\/ (accessed 2022\u201308\u201314)."},{"key":"3139_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.931519","volume":"13","author":"M Ren","year":"2022","unstructured":"Ren M, Zhou X, Zhang Y, Mo F, Yang J, Yu M, Ji F (2022) Effects of bariatric endoscopy on non-alcoholic fatty liver disease: a comprehensive systematic review and meta-analysis. Front Endocrinol (Lausanne) 13:931519. https:\/\/doi.org\/10.3389\/fendo.2022.931519","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"3139_CR97","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/SLA.0000000000000945","volume":"260","author":"R Caiazzo","year":"2014","unstructured":"Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, Raverdy V, Buob D, Pigeyre M, Mathurin P, Pattou F (2014) Roux-En-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 260(5):893\u2013898. https:\/\/doi.org\/10.1097\/SLA.0000000000000945","journal-title":"Ann Surg"},{"issue":"2","key":"3139_CR98","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","volume":"149","author":"G Lassailly","year":"2015","unstructured":"Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P (2015) Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149(2):379\u2013388. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.014","journal-title":"Gastroenterology"},{"key":"3139_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007340.pub2","author":"NC Chavez-Tapia","year":"2020","unstructured":"Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M (2020) Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007340.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"3139_CR100","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/SLA.0000000000002397","volume":"266","author":"P Kalinowski","year":"2017","unstructured":"Kalinowski P, Paluszkiewicz R, Ziarkiewicz-Wr\u00f3blewska B, Wr\u00f3blewski T, Remiszewski P, Grodzicki M, Krawczyk M (2017) Liver function in patients with nonalcoholic fatty liver disease randomized to Roux-En-Y gastric bypass versus sleeve gastrectomy: a secondary analysis of a randomized clinical trial. Ann Surg 266(5):738\u2013745. https:\/\/doi.org\/10.1097\/SLA.0000000000002397","journal-title":"Ann Surg"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-03139-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-022-03139-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-03139-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T11:30:23Z","timestamp":1674819023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-022-03139-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3139"],"URL":"https:\/\/doi.org\/10.1007\/s11739-022-03139-x","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}